High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: A possible relation to lupus nephritis
Restricted accessResearch articleFirst published online December, 2022
High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: A possible relation to lupus nephritis
The aim of this study was to evaluate the effects of the high mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphisms on systemic lupus erythematosus (SLE) development and investigate their link to lupus nephritis (LN).
Methods
We enrolled 120 Egyptian SLE patients and 120 healthy controls. Thorough medical and clinical evaluation were carried out, and SLE disease activity index (SLEDAI) was assessed. Lupus patients were divided into two groups according to the presence of LN. Measurement of HMGB1 serum and urinary levels was done using ELISA and genotyping for HMGB1 (rs1045411) was performed.
Results
There were statistically significantly higher HMGB1 serum and urinary levels in SLE patients (p < 0.001). There was a marginally significant association between lupus and alleles (p = 0.059, φ = −0.086). ‘C’ allele was marginally significant risk allele for SLE. After classifying SLE patients based on the presence or absence of LN, there was no significant difference as regard sex (p = 0.387), age (p = 0.208) and disease duration (p = 0.094).However, there was a significant difference between the 2 groups in regard to the frequency of musculoskeletal manifestations (p = 0.035), SLEDAI score (p < 0.001), both serum (p < 0.001) and urinary HMGB1 levels (p < 0.001) in addition to the frequency of HMGB1 genotypes (p = 0.003). Lupus patients with C/T-T/T HMGB1 genotypes had 3.5-times higher odds to exhibit LN.
Conclusions
Serum and urine HMGB1 measurements are helpful in the diagnosis of SLE and the prediction of LN. There is a link between HMGB1 gene variations and the risk of SLE, with evidence that the C/T-T/T HMGB1 genotype is linked to a significantly greater risk of LN in the Egyptian population.
TamirouFArnaudLTalaricoR, et al.Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open2018; 4: e000793.
2.
SalehMEltorabyEETharwatS, et al.Clinical and histopathological features and short-term outcomes of lupus nephritis: a prospective study of 100 Egyptian patients. Lupus2020; 29: 993–1001.
3.
TsokosGCLoMSCosta ReisP, et al.New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol2016; 12: 716–730.
4.
TeruelMAlarcón-RiquelmeME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun2016; 74: 161–175.
5.
MohanCPuttermanC. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol2015; 11: 329–341.
6.
ZhouT-BLiuY-GLinN, et al.Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and systemic lupus erythematosus/lupus nephritis: a systematic review and metaanalysis. J Rheumatol2012; 39: 686–693.
7.
GoodwinGHSandersCJohnsEW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem1973; 38: 14–19.
8.
YanaiHBanTTaniguchiT. Essential role of high-mobility group box proteins in nucleic acid-mediated innate immune responses. J Intern Med2011; 270: 301–308.
9.
AnderssonUYangHHarrisH. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets2018; 22: 263–277.
10.
PisetskyDS. The complex role of DNA, histones and HMGB1 in the pathogenesis of SLE. Autoimmunity2014; 47: 487–493.
11.
SchaperFde LeeuwKHorstG, et al.Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus. Clin Exp Immunol2017; 188: 412–419.
ChenQGuanXZuoX, et al.The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm Sin B2016; 6: 183–188.
14.
ChouYEYangPJLinCY, et al.The impact of HMGB1 polymorphisms on prostate cancer progression and clinicopathological characteristics. Int J Environ Res Public Health2020; 17: 7247.
15.
YueLZhangQHeL, et al.Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population. J Cell Mol Med2016; 20: 1966–1973.
16.
Abd El AzeemRAZedanMMSaadEA, et al.Single-nucleotide polymorphisms (SNPs) of antioxidant enzymes SOD2 and GSTP1 genes and SLE risk and severity in an Egyptian pediatric population. Clin Biochem2021; 88: 37–42.
17.
RenD-FZhangJ. Single-nucleotide polymorphisms of peroxisome proliferator-activated receptor-γ are associated with systemic lupus erythematosus in a Chinese Han population. Clin Exp Dermatol2016; 41: 541–546.
18.
PetriMOrbaiA-MAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
SelvarajaMAbdullahMAripM, et al.Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis. Plos One2019; 14: e0224707.
21.
LeeYHChoiSJJiJD, et al.Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus2016; 25: 727–734.
22.
DörnerTFurieR. Novel paradigms in systemic lupus erythematosus. Lancet2019; 393: 2344–2358.
23.
GordonCAmissah-ArthurMBGayedM, et al.The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford)2018; 57: e1–e45.
24.
LuHZhangZBarniePA, et al.Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury. Cytokine Growth Factor Rev2019; 47: 74–82.
25.
PaudelYNShaikhMFChakrabortiA, et al.HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci2018; 12: 628.
26.
TangDKangRVan HoutenB, et al.High mobility group box 1 (HMGB1) phenotypic role revealed with stress. Mol Med2014; 20: 359–362.
27.
WangMGauthierADaleyL, et al.The role of HMGB1, a nuclear damage-associated molecular pattern molecule, in the pathogenesis of lung diseases. Antioxid Redox Signal2019; 31: 954–993.
28.
YamamotoTTajimaY. HMGB1 is a promising therapeutic target for acute liver failure. Expert Rev Gastroenterol Hepatol2017; 11: 673–682.
29.
BuckleyCDGilroyDWSerhanCN, et al.The resolution of inflammation. Nat Rev Immunol2013; 13: 59–66.
30.
FanHTangH-BChenZ, et al.Inhibiting HMGB1-RAGE axis prevents pro-inflammatory macrophages/microglia polarization and affords neuroprotection after spinal cord injury. J Neuroinflammation2020; 17: 295.
31.
YanaiHBanTWangZ, et al.HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature2009; 462: 99–103.
32.
TaniguchiNKawaharaKYoneK, et al.High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum2003; 48: 971–981.
33.
BanchereauJPascualV. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity2006; 25: 383–392.
34.
TanakaAItoTKibataK, et al.Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. Lupus2019; 28: 1120–1127.
35.
WenZXuLChenX, et al.Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol2013; 190: 5411–5422.
36.
MaCJiaoYZhangJ, et al.Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus. Rheumatol Int2012; 32: 395–402.
37.
AbdulahadDAWestraJBijzetJ, et al.High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther2011; 13: R71.
38.
ZhangCLiCJiaS, et al.High-mobility group box 1 inhibition alleviates lupus-like disease in BXSB mice. Scand J Immunol2014; 79: 333–337.
39.
AbdulahadDAWestraJBijzetJ, et al.Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations. Arthritis Res Ther2012; 14: R184.
40.
JogNRBlancoILeeI, et al.Urinary high-mobility group box-1 associates specifically with lupus nephritis class V. Lupus2016; 25: 1551–1557.
41.
KangRChenRZhangQ, et al.HMGB1 in health and disease. Mol Aspects Med2014; 40: 1–116.
42.
de SouzaAWSWestraJLimburgPC, et al.HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev2012; 11: 909–917.
43.
SinghAFengYMahatoN, et al.Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis. J Inflamm Res2015; 8: 71–77.
44.
UedaMTakahashiYShindenY, et al.Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res2014; 34: 5357–5362.
